scholarly journals Biological Therapy for Asthma

2021 ◽  
Vol 7 (1) ◽  
pp. 27
Author(s):  
Resti Yudhawati ◽  
Megawati Rif’atyyah Nozomi Guntur
Keyword(s):  
Targeted Therapy ◽  
Biological Therapy ◽  
Chronic Inflammatory Disease ◽  
Interleukin 4 ◽  
Interleukin 17 ◽  
Asthma Therapy ◽  
Biological Therapies ◽  
Interleukin 5 ◽  
Asthma Phenotypes ◽  
Molecular Pathophysiology

Asthma is a heterogeneous chronic inflammatory disease in the respiratory tract that leads to recurrent episodic symptoms. Study about the mechanism of pathophysiology and immunology which stimulates chronic inflammation in asthma has been greatly developed. The understanding of inflammation mediator that is predominant on various asthma phenotypes could be useful for development of diagnosis and targeted therapy. Standard asthma therapy administered through the airway has limited effects only in the airway. The knowledge of molecular pathophysiology and immunology of this disease developed interest of the drugs that perform proximally from inflammation process in the airway, in this case is biological therapy. Several biological therapies have been investigated for its efficacy on human, including Anti IgE (Omalizumab), Anti Interleukin-5 (Mepolizumab, Reslizumab, Benralizumab), Anti Interleukin-4/Interleukin-13 (Dupilumab), and Anti Interleukin-17 (Secukinumab and Brodalumab).

scholarly journals Persistence and Adherence to Biologic Therapies in Juvenile Idiopathic Arthritis

2021 ◽  
Author(s):  
Juan Carlos Nieto-González ◽  
Laura Trives ◽  
Alejandra Melgarejo-Ortuño ◽  
Aranzazu Ais ◽  
Belen Serrano-Benavente ◽  
...  
Keyword(s):  
Biological Therapy ◽  
Medication Possession Ratio ◽  
Chronic Inflammatory Disease ◽  
First Year ◽  
Biological Therapies ◽  
Adherence To Treatment ◽  
Kaplan Meier ◽  
Persistence Rate ◽  
Remission Criteria ◽  
Control Disease

Abstract BackgroundJuvenile Idiopathic Arthritis (JIA) is a chronic inflammatory disease that often requires the use of biological therapies to control disease activity. Persistence and adherence to treatment are important aspects on which we have scarce information.MethodsWe performed a longitudinal, retrospective, and observational study based on daily clinical management of JIA patients. We calculated the clinical remission status at 6 and 12 months. Persistence of biological therapy was evaluated by Kaplan-Meier curves and adherence by the Medication Possession Ratio (MPR).ResultsWe included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third biological, respectively. Persistence rate of biological therapies at 5 years was 64%, with no differences between the first and second biological line. Adherence was high the first year of treatment (MPR80: 96.3%) as well as the second and third years (MPR80: 85.2% and 91.8% respectively).ConclusionsPersistence and adherence to biological therapies were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of accomplishing Wallace remission criteria at 6 months, but it was not confirmed at 12 months.

Interleukin-4, interferon-gamma and interleukin-5 in peripheral blood of children with moderate atopic asthma

1997 ◽  
Vol 27 (11) ◽  
pp. 1254-1260 ◽  
Author(s):  
M. O. HOEKSTRA ◽  
Y. HOEKSTRA ◽  
D. DE REUS ◽  
B. RUTGERS ◽  
J. GERRITSEN ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Peripheral Blood ◽  
Atopic Asthma ◽  
Interleukin 4 ◽  
Interleukin 5

Levels interleukine-4 and interleukin-17 (IL-4, IL-17) of blood in patients with habitual recurrent pregnancy loss, which occurred in a loop in vitro fertilization

2016 ◽  
pp. 137-139
Author(s):  
K.P. Golovatyuk ◽  
Keyword(s):  
In Vitro Fertilization ◽  
Conditioned Medium ◽  
Mononuclear Cells ◽  
Recurrent Miscarriage ◽  
Interleukin 4 ◽  
Control Group ◽  
Interleukin 17 ◽  
Vitro Fertilization ◽  
Blood Mononuclear Cells

The objective: was to investigate the levels of cytokines IL-4 and IL-17 in serum and conditioned medium cultures of blood mononuclear cells (MNC) and evaluation association between their products and miscarriage, which occurred in IVF cycles. Patients and methods. We observed 240 patients with recurrent miscarriage, came in IVF cycles, and 100 apparently healthy fertile women in the control group. The concentrations of IL-4 and IL-17 in serum and conditioned medium of MNC cultures were determined. Results. The levels of IL-4 in the serum and conditioned medium in spontaneous and stimulated mitogen secretion was not significantly different from those in the control group, whereas IL-17 levels were higher than those in the control group serum, in conditioned media of stimulated and non-stimulated MNCs. Conclusion. Disregulation of activity of circulating blood mononuclear cells in women with recurrent miscarriage that followed IVF, is accompanied by increased secretion of IL-17 and almost constant production of IL-4 on the back of high stimulation index of production of these cytokines. Key words: in vitro fertilization, miscarriage, interleukin-4, interleukin-17, serum stimulated and non-stimulated mononuclear blood.

Biological therapy of allergic diseases during the COVID-19 pandemic

2020 ◽  
Vol 17 (3) ◽  
pp. 115-120
Author(s):  
Elena S. Fedenko ◽  
Olga G. Elisyutina ◽  
Natalia I. Il`ina
Keyword(s):  
Biological Therapy ◽  
Treatment Approach ◽  
Allergic Diseases ◽  
Scientific Data ◽  
Biological Therapies ◽  
Active Infection ◽  
The Past ◽  
Type 2 Immune Response ◽  
Antiviral Medications

The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic started in December 2019 in Wuhan, China, continued to spread across the globe and spanned 188 countries. Under the new circumstances treatment approach for T2 allergic diseases such as asthma, chronic hives, atopic dermatitis, and sinusitis with polyps has been changed. In the past years, new biological therapies monoclonal antibodies for these diseases have been developed targeting different aspects of the type 2 immune response. New knowledge on the COVID-19 disease course raises many issues around the safety of biologicals in patients with active infection, as well as their interactions with antiviral medications. In Russia new biological therapies entered clinical practice but its effectiveness and safety still are not known. This newsletter is based on Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement and the latest scientific data.

scholarly journals Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

2021 ◽  
Vol 11 (11) ◽  
pp. 4865
Author(s):  
Marta Amigo-Basilio ◽  
Covadonga Álvarez-González ◽  
Carlos Cobo-Vázquez ◽  
Isabel Leco-Berrocal ◽  
Luis Miguel Sáez-Alcaide ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Conservative Treatment ◽  
Adverse Effects ◽  
Adverse Events ◽  
Oral Cavity ◽  
Study Design ◽  
Biological Therapy ◽  
Design Analysis ◽  
Biological Therapies ◽  
Analysis Of Cases

Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients undergoing treatment with biological therapies who have developed adverse effects associated with these drugs. Results: Of the 62 articles reviewed, 49 describe 68 cases of MRONJ, most of which appeared in the jaw and received surgical and/or conservative treatment. Conclusions: Biological therapies can potentially develop adverse effects in the oral cavity, so strict monitoring by the dentist is necessary.

Effect of Theaflavin on Inflammatory and Remolding of Airway in the Asthma Mice

2021 ◽  
Vol 11 (6) ◽  
pp. 1091-1098
Author(s):  
Jingju Hu ◽  
Jing Yang ◽  
Hua Guo ◽  
Xuesong Yao ◽  
Haiyan Qiu ◽  
...  
Keyword(s):  
Interleukin 4 ◽  
Control Group ◽  
Model Group ◽  
Interleukin 5 ◽  
Treatment Groups ◽  
Interleukin 13 ◽  
Asthma Model ◽  
Lung Resistance ◽  
Neutrophile Granulocytes ◽  
Number Of Cells

To study the effect of theaflavin on the airway’s inflammation and remodeling in mice with asthma. The mice were divided into the control, asthma model, and the theaflavin treatment groups to analyze the changes in pulmonary compliance and lung resistance of the mice with asthma to theaflavin treatment. The theaflavin treatment groups consisted of the low-dose (15 mg/kg theaflavin-intragastric administration), medium-dose (30 mg/kg), and high-dose (60 mg/kg) groups. Alveoli lavage liquid was gathered from the mice to count the number of inflammatory cells, and the levels of interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 13 (IL-13), and eotaxin were detected by ELISA. The levels of proteins, such as transforming growth factor-1 (TGF-1), alpha-smooth muscle actin (α-SMA), CyclinD1,CyclinD2, Toll-like receptors-4 (TLR4), myeloid differentiation factor 88 (MyD88), and NF-κBp65, which showed the performance of lung tissue was tested by Western blotting. Compared to the control group, the lung resistance of the asthma model mice was increased, and compliance was decreased after increasing concentrations of acetylcholine (Mch) stimulation. Compared to the asthma model group, the pulmonary resistance was decreased, and pulmonar compliance was increased according to the rising concentration of Mch in theaflavin-L, theaflavin-M and theaflavin-H mice. Compared to the control group, the number of cells, macrophages, acidophilic cells, lymph, and neutrophile granulocytes increased in the alveolar perfusion fluid of asthmatic mice. The level of interleukin 4, interleukin 5, interleukin 13, and eotaxin, TGF-β1, α-SMA, Cyclin D1, MyD88, TLR4, Cyclin D2, and NF-κBp65 proteins of the lung was also increased. Compared to the model group, the number of cells, macrophages, acidophilic cells, lymph, and neutrophile granulocytes were decreased successively in the alveolar lavage fluid in the theaflavin-L, theaflavin-M, and theaflavin-H mice. Meanwhile, the content of interleukin 4, interleukin 5, interleukin 13, and eotaxin were decreased successively, and the level of TGF-β1, α-SMA, Cyclin D1, MyD88, TLR4, Cyclin D2, and NF-Bp65 protein increased successively in the theaflavin-L, theaflavin-M, and theaflavin-H mice. Theaflavin has been found to reduce airway inflammation, impede airway remodeling, and decrease the TLR 4/MyD88/NF-B signaling in asthmatic mice.

Sign in / Sign up

Export Citation Format

Share Document